Delivery Order SPE2DB20D1109-SPE2DB25FP77Y
- Not listed
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $1,054.35. This is a firm fixed price, non-set-aside delivery order executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through December 2026. The performance...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 18, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, valued at $10,185.62. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The order is expected to be completed by November 19, 2025, with performance occurring at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order represents a child...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $1,112.07. This firm fixed-price contract, which is not set-aside and was competitively awarded, will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 26, 2025. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $5,863.86 delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of August 21, 2025. The product will be delivered to the contractor's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $2,108.70. This competitively awarded, non-set-aside contract represents a firm fixed price delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a $1,054.50 delivery order to AmerisourceBergen Drug Corp on October 15, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The order is scheduled for completion by October 16, 2025, with performance at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 23, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, valued at $8,434.80. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of September 24, 2025. This delivery order is...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $10,646.49 to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. The contract, which was not set-aside and was competitively awarded, was executed on June 17, 2025, with an ultimate completion date of June 18, 2025. Performance will take place at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,830.66 to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. The award was made on November 24, 2025, under a firm fixed-price contract type with an ultimate completion date of November 25, 2025. This delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $53,916.19 to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This competitively awarded, firm fixed-price delivery order was issued on October 8, 2025, with an ultimate completion date of October 9, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger Indefinite...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB25FP77YDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $4,966.59. This is a firm fixed-price delivery order with no set-aside designation, performed at the contractor's corporate office location in Conshohocken, Pennsylvania, and scheduled for completion by September 18, 2025. The order is issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive pharmaceutical prime vendor agreement running through December 2026 that serves military healthcare systems globally. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal vendor specializing in medical supply chain support for defense and veteran healthcare programs. The company maintains an extensive portfolio of competitive federal contract awards with DLA covering a wide range of pharmaceutical products, including specialty medications, diabetes treatments, and medical devices across multiple therapeutic domains. This particular delivery order for insulin represents a routine procurement fulfilling the ongoing pharmaceutical supply needs of military and defense healthcare beneficiaries supported through the DLA's global medical supply network.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.0k | 9/17/25 |